Is Trending Stock Organon & Co. (OGN) a Buy Now?
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) Q3 Earnings and Revenues Beat Estimates
Organon (OGN) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.87 per share a year ago.
The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products
Organon & Co. shares plunged Monday, October 27th, after CEO Kevin Ali resigned amid an audit committee investigation into wholesaler sales irregularities. Despite the scandal, OGN's valuation at $7 per share is extremely cheap compared to peers, with a diversified product portfolio and global reach. The main risk is OGN's heavy $8.3 billion net debt load, which could hinder share price recovery if revenue growth remains sluggish.
Organon (OGN) Laps the Stock Market: Here's Why
The latest trading day saw Organon (OGN) settling at $9.05, representing a +1.23% change from its previous close.
Organon (OGN) Earnings Expected to Grow: Should You Buy?
Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Organon (OGN) closed at $9.28, marking a -1.07% move from the previous day.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
